December 7, 2016 / 12:05 AM / 3 years ago

EU clears Bristol-Myers immunotherapy drug for blood cancer

LONDON (Reuters) - Bristol-Myers Squibb’s immunotherapy drug Opdivo has been approved in Europe for the treatment of classical Hodgkin lymphoma, a rare blood cancer, the U.S. company said on Wednesday.

Opdivo is already approved for melanoma, lung cancer and kidney cancer.

Reporting by Ben Hirschler. Editing by Jane Merriman

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below